The iconic rise of Viagra has long been a symbol of pharmaceutical success, but its position within the broader industry now raises questions about long-term yields . Alternative versions are eroding exclusivity , leading to worries that investing in companies closely tied to Viagra's former position could be a problematic decision , especially giv